These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32655270)

  • 1. Transjugular intrahepatic portosystemic shunt for pyrrolizidine alkaloid-related hepatic sinusoidal obstruction syndrome.
    Zhou CZ; Wang RF; Lv WF; Fu YQ; Cheng DL; Zhu YJ; Hou CL; Ye XJ
    World J Gastroenterol; 2020 Jun; 26(24):3472-3483. PubMed ID: 32655270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt.
    Xiao J; Tu J; Zhang H; Zhang F; Zhang W; Xu H; Yin Q; Yang J; Han H; Wang Y; Zhang B; Peng C; Zou X; Zhang M; Zhuge Y
    Hepatol Int; 2021 Jun; 15(3):720-729. PubMed ID: 33507485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of PA-HSOS severity grading to predict the prognosis of patients with PA-HSOS treated by transjugular intrahepatic portosystemic shunt].
    Chen YR; Zhang W; Zhang M; Zhang F; Xiao JQ; Yin Q; Zhuge YZ
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):46-53. PubMed ID: 33541023
    [No Abstract]   [Full Text] [Related]  

  • 4. Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis.
    Li S; Li Y; Zhou C; Li H; Chen C; Peng C; Wang T; Liu F; Xiao J; Shi L
    Cardiovasc Intervent Radiol; 2023 Jul; 46(7):931-942. PubMed ID: 37225971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transjugular intrahepatic portosystemic shunt for pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective cohort study.
    Huang T; Zhang X; Yan K; Lou D; He Y; Dai S; Zheng D; Chen P; Wu F; Gu L
    Eur J Gastroenterol Hepatol; 2023 Sep; 35(9):1004-1011. PubMed ID: 37395216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
    Huang Q; Zhang Q; Xu H; Zu M; Xiao J; Shen B
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):445-452. PubMed ID: 36719828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
    Wu F; Yu J; Gan H; Zhang H; Tian D; Zheng D
    Sci Rep; 2021 Nov; 11(1):21743. PubMed ID: 34741082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.
    Yang XQ; Ye J; Li X; Li Q; Song YH
    World J Gastroenterol; 2019 Jul; 25(28):3753-3763. PubMed ID: 31391770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum.
    Zhang L; Li Q; Makamure J; Zhao D; Liu Z; Zheng C; Liang B
    BMC Gastroenterol; 2021 Jan; 21(1):26. PubMed ID: 33423668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.
    Zhuge Y; Liu Y; Xie W; Zou X; Xu J; Wang J;
    J Gastroenterol Hepatol; 2019 Apr; 34(4):634-642. PubMed ID: 30669184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transjugular intrahepatic portosystemic shunt for the treatment of hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids: A multicenter retrospective study.
    Wang C; Wang Y; Zhao J; Yang C; Zhu X; Niu H; Sun J; Xiong B
    Heliyon; 2024 Jan; 10(1):e23455. PubMed ID: 38163189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics, CT signs, and pathological findings of Pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study.
    Liu F; Rong X; Guo H; Xu D; Liu C; Meng L; Yang X; Guo T; Kan X; Song Y
    BMC Gastroenterol; 2020 Feb; 20(1):30. PubMed ID: 32019495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids.
    Du X; Liu Z; Yu H; Wang Y; Zou Z; Wei H; Liang J; Yang D; Liu Y; Zhang J; Pan CQ
    Medicine (Baltimore); 2023 Aug; 102(32):e34698. PubMed ID: 37565875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of Gynura-segetum-related hepatic sinus obstruction syndrome complicated with alcoholic liver disease.
    Gao Y; Zhang X; Zhou X; Wang J; Gong L; Chen G
    J Pak Med Assoc; 2024 Jul; 74(7):1355-1357. PubMed ID: 39028070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.
    Luo SH; Chu JG; Huang H; Zhao GR; Yao KC
    World J Gastroenterol; 2019 Mar; 25(9):1088-1099. PubMed ID: 30862997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature.
    Campos-Varela I; Castells L; Dopazo C; Pérez-Lafuente M; Allende H; Len O; Llopart L; Vargas V; Charco R
    Liver Transpl; 2012 Feb; 18(2):201-5. PubMed ID: 21656652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transjugular intrahepatic portosystemic shunt
    Philipp M; Blattmann T; Bienert J; Fischer K; Hausberg L; Kröger JC; Heller T; Weber MA; Lamprecht G
    World J Gastroenterol; 2022 Nov; 28(41):5944-5956. PubMed ID: 36405105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of poor prognosis in patients with pyrrolidine alkaloids induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt : Transjugular intrahepatic portosystemic shunt in patients with sinusoidal obstruction syndrome, etiology matters.
    Magaz M; García-Pagán JC
    Hepatol Int; 2021 Jun; 15(3):568-570. PubMed ID: 33733320
    [No Abstract]   [Full Text] [Related]  

  • 19. Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome.
    He FL; Wang L; Zhao HW; Fan ZH; Zhao MF; Dai S; Yue ZD; Liu FQ
    World J Gastroenterol; 2015 Feb; 21(8):2413-8. PubMed ID: 25741149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
    Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
    World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.